A Measured Reduction in a Deep-Value Position On Sept. 15, 2026, Lagoda Investment Management, L.P. (Trades, Portfolio) reduced its position in VolitionRX Ltd (
A Measured Reduction in a Deep-Value Position On Sept.
15, 2026, Lagoda Investment Management, L.P. (Trades, Portfolio) reduced its position in VolitionRX Ltd (
A Measured Reduction in a Deep-Value Position
On Sept. 15, 2026, Lagoda Investment Management, L.P. (Trades, Portfolio) reduced its position in VolitionRX Ltd (VNRX) by 1,500 shares, a change of -0.09%. The shares were traded at a price of $0.2893. Following the transaction, the firm holds 1,650,505 shares of VNRX. This position represents 0.26% of the firm's portfolio and 5.90% of the company's outstanding shares. While the absolute number of shares sold is modest relative to the total holding, the transaction is notable because it marks a slight pullback from a micro-cap diagnostics name that has suffered a dramatic collapse in market value over the past year. The trade leaves the firm with a residual stake that still ranks among the larger positions in VNRX, suggesting the reduction was a tactical adjustment rather than a full exit from the investment.
Lagoda Investment Management: A New York-Based Equity Manager
Lagoda Investment Management, L.P. (Trades, Portfolio) is a New York-based investment firm located at 3 Columbus Circle, New York, NY 10019. The firm manages an equity portfolio valued at approximately $182 million, with holdings in 25 stocks. Its top holdings include Advanced Micro Devices Inc AMD, Alphabet Inc GOOG, Natera Inc NTRA, Texas Pacific Land Corp TPL, and Taiwan Semiconductor Manufacturing Co Ltd TSM. The firm's primary sector exposures are Technology and Healthcare, a mix that pairs high-growth semiconductor and internet names with more defensive, innovation-driven medical companies. The presence of Natera, a molecular diagnostics company, alongside VolitionRX suggests the firm maintains a dedicated interest in the diagnostics space, even as it trims exposure to individual names within that theme.
VolitionRX: An Epigenetics Diagnostics Platform
VolitionRX Ltd is a US-based epigenetics company that develops blood-based diagnostic tests through its Nucleosomics platform, which identifies and measures nucleosomes in blood or other bodily fluids as indicators of disease. Its subsidiaries pursue applications in human diagnostics and monitoring, including cancer and diseases associated with NETosis, as well as veterinary diagnostics. The company's tests are designed to be simple, cost-effective, and minimally invasive, targeting clinicians, laboratories, and healthcare providers. VolitionRX generates revenue primarily through research collaborations, licensing arrangements, and grant funding while advancing its product pipeline toward regulatory approval and commercialization. Its operations span the United States, Europe, and Asia, with research and development activities concentrated in Belgium and the United States. VolitionRX has a market capitalization of $7.394 million and is classified within the Medical Devices & Instruments industry.
Stock Performance and GF Value Assessment
The stock's current price is $0.2649, reflecting a decline of 8.43% since the transaction date. Year-to-date, the stock has fallen 95.15%, and since its IPO on April 25, 2007, it has declined 93.38%. The GF Value, GuruFocus's exclusive estimate of intrinsic value, stands at $17.76, while the price-to-GF Value ratio is 0.01. The GF Valuation indicates "Possible Value Trap, Think Twice," suggesting the stock may be undervalued but carries significant risk. The stock has a GF Score of 50 out of 100, indicating poor future performance potential. This combination of an extremely low price-to-GF Value ratio and a cautionary valuation warning is central to understanding the firm's decision to reduce rather than add to the position.
Averytin News Financial update.